Hot Features
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome prolifer... Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.55 | 16.7682926829 | 3.28 | 4.045 | 3.265 | 436047 | 3.62608254 | DE |
| 4 | 0.49 | 14.6706586826 | 3.34 | 4.045 | 2.88 | 337544 | 3.31239844 | DE |
| 12 | -0.88 | -18.6836518047 | 4.71 | 5.05 | 2.88 | 365509 | 3.90622946 | DE |
| 26 | -1.065 | -21.7568947906 | 4.895 | 6.2 | 2.88 | 377616 | 4.64078184 | DE |
| 52 | 1.02 | 36.2989323843 | 2.81 | 6.2 | 2.645 | 362288 | 4.28766486 | DE |
| 156 | 0.1 | 2.68096514745 | 3.73 | 6.2 | 1.434 | 144059 | 4.02600634 | DE |
| 260 | -7.83 | -67.1526586621 | 11.66 | 13 | 1.434 | 106552 | 4.2689317 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.